Silence Therapeutics (SLN) Total Liabilities (2019 - 2025)
Silence Therapeutics (SLN) has disclosed Total Liabilities for 7 consecutive years, with $69.1 million as the latest value for Q4 2025.
- Quarterly Total Liabilities rose 0.77% to $69.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $69.1 million through Dec 2025, up 0.77% year-over-year, with the annual reading at $69.1 million for FY2025, 0.77% up from the prior year.
- Total Liabilities hit $69.1 million in Q4 2025 for Silence Therapeutics, down from $72.7 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $118.2 million in Q4 2021 to a low of -$156.8 million in Q1 2024.
- Historically, Total Liabilities has averaged $22.0 million across 5 years, with a median of $71.1 million in 2025.
- Biggest five-year swings in Total Liabilities: decreased 27.99% in 2024 and later skyrocketed 157.4% in 2025.
- Year by year, Total Liabilities stood at $118.2 million in 2021, then fell by 15.21% to $100.2 million in 2022, then decreased by 4.91% to $95.3 million in 2023, then decreased by 27.99% to $68.6 million in 2024, then increased by 0.77% to $69.1 million in 2025.
- Business Quant data shows Total Liabilities for SLN at $69.1 million in Q4 2025, $72.7 million in Q3 2025, and $71.1 million in Q2 2025.